share_log

SciSparc | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

SciSparc | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

SciSparc | 425:募資說明/企業合併公告
美股SEC公告 ·  04/12 21:27

Moomoo AI 已提取核心訊息

SciSparc Ltd., a clinical-stage pharmaceutical company, has entered into a merger agreement with AutoMax Motors Ltd., an Israeli vehicle importer. The agreement stipulates that SciSparc will acquire 100% of AutoMax, establishing a new wholly-owned subsidiary that will merge with AutoMax, making it a wholly-owned subsidiary of SciSparc. Post-acquisition, SciSparc shareholders are expected to hold approximately 50.01% of the combined company, while AutoMax equity holders will hold around 49.99%, subject to adjustments. SciSparc has committed to having at least $4.25 million in net cash at closing. The acquisition is contingent upon regulatory approvals, Israeli court approvals, and shareholder approvals from both companies. The transaction aligns with SciSparc's June 2022 announcement to explore strategic transactions to maximize shareholder value. The company's ongoing pharmaceutical operations will continue post-acquisition. The merger agreement is subject to various approvals, including compliance with regulatory requirements and approvals from SciSparc and AutoMax shareholders.
SciSparc Ltd., a clinical-stage pharmaceutical company, has entered into a merger agreement with AutoMax Motors Ltd., an Israeli vehicle importer. The agreement stipulates that SciSparc will acquire 100% of AutoMax, establishing a new wholly-owned subsidiary that will merge with AutoMax, making it a wholly-owned subsidiary of SciSparc. Post-acquisition, SciSparc shareholders are expected to hold approximately 50.01% of the combined company, while AutoMax equity holders will hold around 49.99%, subject to adjustments. SciSparc has committed to having at least $4.25 million in net cash at closing. The acquisition is contingent upon regulatory approvals, Israeli court approvals, and shareholder approvals from both companies. The transaction aligns with SciSparc's June 2022 announcement to explore strategic transactions to maximize shareholder value. The company's ongoing pharmaceutical operations will continue post-acquisition. The merger agreement is subject to various approvals, including compliance with regulatory requirements and approvals from SciSparc and AutoMax shareholders.
臨床階段的製藥公司ScisPARC Ltd. 已與以色列汽車進口商AutoMax Motors Ltd.簽訂了合併協議。該協議規定,ScisPARC將收購AutoMax100%的股份,成立一家新的全資子公司,該子公司將與AutoMax合併,使其成爲ScisPARC的全資子公司。收購後,ScisPARC的股東預計將持有合併後公司約50.01%的股份,而AutoMax的股東將持有約49.99%的股份,視調整而定。ScisPARC已承諾在收盤時擁有至少425萬美元的淨現金。此次收購取決於監管部門的批准、以色列法院的批准以及兩家公司的股東批准。該交易與ScisPARC於2022年6月宣佈的探索戰略交易以最大化股東價值的聲明一致。該公司正在進行的製藥業務將在收購後繼續。合併協議需要獲得各種批准,包括遵守監管要求以及ScisPARC和AutoMax股東的批准。
臨床階段的製藥公司ScisPARC Ltd. 已與以色列汽車進口商AutoMax Motors Ltd.簽訂了合併協議。該協議規定,ScisPARC將收購AutoMax100%的股份,成立一家新的全資子公司,該子公司將與AutoMax合併,使其成爲ScisPARC的全資子公司。收購後,ScisPARC的股東預計將持有合併後公司約50.01%的股份,而AutoMax的股東將持有約49.99%的股份,視調整而定。ScisPARC已承諾在收盤時擁有至少425萬美元的淨現金。此次收購取決於監管部門的批准、以色列法院的批准以及兩家公司的股東批准。該交易與ScisPARC於2022年6月宣佈的探索戰略交易以最大化股東價值的聲明一致。該公司正在進行的製藥業務將在收購後繼續。合併協議需要獲得各種批准,包括遵守監管要求以及ScisPARC和AutoMax股東的批准。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息